Ac immune reports third quarter 2023 financial results and provides a corporate update

Ac immune reports third quarter 2023 financial results and provides a corporate update results from amyloid plaque reduction analysis (abeta-pet) after 6 months of treatment with aci-24.060 in abate phase 1b/2 study on track for h1 2024 aci-24.060 abate interim safety and immunogenicity data in alzheimer's disease (ad) expected by year-end aci-7104.056 alpha-synuclein active immunotherapy in phase 2 ‘vacsyn' parkinson's disease (pd) trial to complete cohort 1 enrollment and report initial safety findings by year-end cash position of chf 79.9 million finances the company into q4 2024, excluding the benefit of anticipated milestone payments lausanne, switzerland, november 3, 2023 – ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the third quarter ended september 30, 2023, and provided a corporate update. dr. andrea pfeifer, ceo of ac immune sa, commented: “as we look to year-end and into 2024, ac immune is poised to achieve multiple milestones across our clinical programs.
ACIU Ratings Summary
ACIU Quant Ranking